Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 119 Squamous Cell Carcinoma of Head and Neck 60 Melanoma 57 Parkinson Disease 4, Autosomal Dominant Lewy Body 46 Lung Neoplasms 45 Triple Negative Breast Neoplasms 44 Neoplasm Metastasis 42 Breast Neoplasms 40 Neoplasms 36 Colorectal Neoplasms 31 Head and Neck Neoplasms 27 Endometrial Neoplasms 26 Carcinoma, Renal Cell 26 Ovarian Neoplasms 23 Carcinoma, Transitional Cell 22 Urinary Bladder Neoplasms 20 Stomach Neoplasms 15 Carcinoma 14 Pancreatic Neoplasms 13 Uterine Cervical Neoplasms 12 Recurrence 12 Esophageal Neoplasms 12 Sarcoma 11 Hodgkin Disease 11 Brain Neoplasms 11 Carcinoma, Squamous Cell 10 Cholangiocarcinoma 9 Carcinoma, Hepatocellular 9 Skin Neoplasms 8 Esophageal Squamous Cell Carcinoma 8

Interventions

pembrolizumab 1 liposomal doxorubicin 1 Paclitaxel 1 Gemcitabine 1 Carboplatin 1 Bevacizumab 1 1-dodecylpyridoxal 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Ovarian Cancer Recurrent × pembrolizumab × 90 days × Clear all

NCT06843447 2026-05-26

MK-5909-003

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting

Ovarian Cancer Recurrent

Data powered by HemOnc (CC BY 4.0) Colophon ⚡